First Tracks Biotherapeutics Stock

First Tracks Biotherapeutics Equity

The The Equity of First Tracks Biotherapeutics (TRAX) as of Aug 7, 2026 is 287.49 M USD. In the previous year, The Equity was 391.60 M USD — a change of -26.59% (lower).

Equity

287.49 MUSD

YoY

-26.59%

Last updated:

In 2026, First Tracks Biotherapeutics's equity was 287.49 M USD, a -26.59% increase from the 391.60 M USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

First Tracks Biotherapeutics Stock analysis

What does First Tracks Biotherapeutics do? First Tracks Biotherapeutics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing First Tracks Biotherapeutics's Equity

First Tracks Biotherapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding First Tracks Biotherapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating First Tracks Biotherapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

First Tracks Biotherapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in First Tracks Biotherapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about First Tracks Biotherapeutics stock

The Equity of First Tracks Biotherapeutics is 287.49 M USD in 2026.

The Equity of First Tracks Biotherapeutics changed from 391.60 M USD to 287.49 M USD, representing a -26.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity First Tracks Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's First Tracks Biotherapeutics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — First Tracks Biotherapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — First Tracks Biotherapeutics